Benjamin Edwards Inc. Trims Stock Holdings in Stryker Corporation $SYK

Benjamin Edwards Inc. trimmed its position in Stryker Corporation (NYSE:SYK) by 2.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 160,366 shares of the medical technology company’s stock after selling 3,768 shares during the period. Benjamin Edwards Inc.’s holdings in Stryker were worth $56,382,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in Stryker by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock worth $11,917,396,000 after purchasing an additional 133,892 shares during the period. Alliancebernstein L.P. grew its stake in Stryker by 13.3% in the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after purchasing an additional 741,542 shares during the period. Legal & General Group Plc grew its stake in Stryker by 4.4% in the third quarter. Legal & General Group Plc now owns 2,303,290 shares of the medical technology company’s stock worth $851,457,000 after purchasing an additional 96,662 shares during the period. Corient Private Wealth LLC grew its stake in Stryker by 104.4% in the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after purchasing an additional 1,146,998 shares during the period. Finally, Invesco Ltd. grew its stake in Stryker by 4.5% in the third quarter. Invesco Ltd. now owns 1,864,918 shares of the medical technology company’s stock worth $689,404,000 after purchasing an additional 80,536 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently weighed in on SYK. Leerink Partners began coverage on Stryker in a research note on Monday, April 13th. They issued an “outperform” rating and a $410.00 price target on the stock. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a report on Saturday. JPMorgan Chase & Co. dropped their target price on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a report on Friday. Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a report on Friday. Finally, Citigroup dropped their target price on Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Sixteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $401.43.

Stryker Trading Down 6.3%

Shares of NYSE:SYK opened at $295.43 on Friday. The company has a market cap of $113.15 billion, a P/E ratio of 35.17, a PEG ratio of 1.84 and a beta of 0.92. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21. Stryker Corporation has a 1 year low of $294.55 and a 1 year high of $404.87. The stock’s fifty day moving average price is $345.67 and its 200-day moving average price is $356.95.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.74%. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the previous year, the company earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Sell-side analysts expect that Stryker Corporation will post 14.91 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend was Tuesday, March 31st. Stryker’s dividend payout ratio is presently 41.90%.

Insider Activity

In other news, Director Ronda E. Stryker sold 250,000 shares of the company’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares of the company’s stock, valued at $891,814,566.52. This represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 4.60% of the stock is currently owned by insiders.

Trending Headlines about Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker maintained its FY?2026 outlook — $14.90–$15.10 adjusted EPS and 8%–9.5% organic sales growth — signaling management’s confidence in recovery from the cyber incident. Article Title
• Positive Sentiment: Operational cash flow and net income showed notable improvement year-over-year (operating cash flow jumped and net income rose), which supports longer?term cash generation and capital investment. Article Title
• Neutral Sentiment: Stryker will present at the Bank of America Global Healthcare Conference on May 13 — an opportunity for management to address the cyber recovery and investor questions, but not an immediate catalyst for results. Article Title
• Negative Sentiment: Q1 results missed consensus: adjusted EPS of $2.60 vs. ~ $2.98 expected and revenue of $6.02B vs. ~$6.34B. Management cited a cyber incident that disrupted production, pressured margins and slowed growth — the primary driver of today’s selling pressure. Article Title
• Negative Sentiment: Several Wall Street firms cut Stryker price targets this morning (JPMorgan to $400, Wells Fargo to $418, Needham/BTIG lowered targets) — ratings largely remain buy/overweight but lower targets reduce near?term upside expectations and add selling pressure. Article Title

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.